The risk of complications from COVID-19 is increased in people with underlying health conditions, unvaccinated people, and those in whom the vaccine is less effective. In these people, COVID-19 can sometimes lead to significant medical problems, hospitalisation, and death.
Most people with COVID-19 are treated in the community and so we need to find treatments that are suitable for use in the community.
COVID-19 can cause great suffering, and it stops people from performing their daily activities, affecting their work, education, and caring responsibilities. The purpose of this clinical trial is to find new treatments that help those suffering with COVID-19 at home and in the community get better quicker and without needing to be treated in hospital. To be able to do this, we aim to test individual possible treatments as soon as they become available.
We are testing new antiviral treatments which might have beneficial effects for the treatment of COVID-19, but which may not yet have a license for use in the UK. All of the treatments in the PANORAMIC trial have been approved by the UK Medicines and Health Care Products Regulatory Agency (MHRA) for use in the study. The MHRA regulates the use of all medicines in the UK.
Local Investigators: Prof Paul Little, Prof Nick Francis, Dr Mark Lown
Study team: Led by Oxford – Prof Chris Butler, Prof Richard Hobbs
Funder: The study is funded by the Department of Health and Social Care and the NIHR
Duration: Start date 01/09/2021, end date 31/08/2022, duration 24 months
Website: www.panoramictrial.org
Contact: m.lown@soton.ac.uk
This study is being conducted by the Primary Care Research Centre.
Research theme
Improving use of medicines
Content area
Infections and antibiotics
